Presentation is loading. Please wait.

Presentation is loading. Please wait.

Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions  Ajay Nehra, MD 

Similar presentations


Presentation on theme: "Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions  Ajay Nehra, MD "— Presentation transcript:

1 Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions  Ajay Nehra, MD  Mayo Clinic Proceedings  Volume 84, Issue 2, Pages (February 2009) DOI: / Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions

2 FIGURE Erectile function and return to normal rates after PDE5 inhibitor use in men with erectile dysfunction and hypertension (top), erectile dysfunction and diabetes (middle), and hyperlipidemia/dyslipidemia (bottom). Numbers inside bars represent medication doses in milligrams. B = baseline; CG = comorbid group; IIEF = International Index of Erectile Function; P = placebo; PDE5 = phosphodiesterase type 5; RG = reference group; S = sildenafil; T = tadalafil; V = vardenafil. Mayo Clinic Proceedings  , DOI: ( / ) Copyright © 2009 Mayo Foundation for Medical Education and Research Terms and Conditions


Download ppt "Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions  Ajay Nehra, MD "

Similar presentations


Ads by Google